Download PDF
Am J Perinatol 1996; 13(4): 217-222
DOI: 10.1055/s-2007-994367
ORIGINAL ARTICLE

© 1996 by Thieme Medical Publishers, Inc.

Use of Tissue Type Plasminogen Activator in Neonates: Case Reports and Review of the Literature

Koenraad Smets, Piet Vanhaesebrouck, Dirk Voet, Petra Schelstraete, Paul Govaert
  • Neonatal Intensive Care Unit, University Children's Hospital ‘C. Hooft,’ Gent, Belgium, and Department of Echography, University Hospital, Gent, Belgium
Further Information

Publication History

Publication Date:
04 March 2008 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Recombinant tissue type plasminogen activator (rt-PA) has been used successfully in neonates for resolution of thrombotic processes, both arterial and venous. We report on 2 neonates with vena cava inferior thrombosis and with biochemical evidence of liver dysfunction in whom rt-PA treatment had to be interrupted because of significant bleeding tendency, without complete resolution of the thrombus. Therapy failure may be due to the age of the thrombus and the systemic way of administration, bypassing the site of the thrombus by collateral circulation. Impaired liver function may result in decreased degradation of rt-PA with prolonged effect and higher risk for bleeding complications. We suggest that lower doses should be administered in these patients.

Keywords

Tissue type plasminogen activator - thrombus - collateral circulation